VSee Health (NASDAQ:VSEE) reported its financial and operational results for the fiscal year ended December 31, 2025, on Wednesday, April 1, 2026.
The results highlight a period of significant commercial acceleration and a structural transformation of the company’s balance sheet as it scales its secure telehealth infrastructure for institutional and federal clients.
Total revenue for fiscal 2025 rose to $14,618,184, representing a 40% increase compared to the previous fiscal year.
This growth was largely underpinned by the execution of multi-year institutional contracts, including a previously announced agreement valued at $10 million per year.
Management noted that the top-line expansion coincided with a sharp reduction in operating expenses, as the company optimized its software-delivery model and reduced legacy overhead costs.
The company ended the year with a materially stronger financial position following a series of strategic debt-to-equity conversions.
As of December 31, 2025, VSee Health reported cash and equivalents of $5,266,286.
Operational milestones during the year included VSee Labs receiving FedRAMP High approval, the most stringent federal security authorization.
This designation allows the company to pursue sensitive government and defense-related healthcare contracts, providing a competitive advantage in the high-security segment of the digital health market.